Search
Eftrenonacog alfa
go.drugbank.com/drugs/DB11608Approvedadherence to prophylaxis. … It was first approved by the FDA in March 2014 and later approved by the EMA in May 2016.
Samarium (153Sm) lexidronam
go.drugbank.com/drugs/DB05273ApprovedRadiopharmaceuticals are radioactive agents that may be used to diagnose some diseases by studying the function of the body's organs or to treat certain diseases.Samarium Sm 153 lexidronam is used to help … Samarium Sm 153 lexidronam is a radioactive medication used to treat pain caused by cancer that has spread to the bone. It is a radiopharmaceutical.
Products: T-BONE KAEFPamidronic acid
go.drugbank.com/drugs/DB00282ApprovedInvestigationalPamidronic acid is a second generation, nitrogen containing bisphosphonate similar to [neridronic acid] and [alendronic acid].[A203111] Pamidronic acid was first described in the literature in 1977. … [A203267] The second generation bisphosphonates are less common as third generation bisphosphonates, such as [ibandronic acid], [zoledronic acid], [minodronic acid], and [risedronic acid] are becoming
Dasiglucagon
go.drugbank.com/drugs/DB15226ApprovedAlthough it tends to be more common in type 1 diabetes mellitus, occurring in about 22% to 46% of patients annually, about 7% to 25% of patients with type 2 diabetes mellitus treated with insulin experience … Dasiglucagon is a glucagon analog that acts to increase blood sugar levels.
Categories: Glucagon Receptor AgonistsViloxazine
go.drugbank.com/drugs/DB09185ApprovedInvestigationalWithdrawnIt was first approved in the UK in 1974; however, the immediate-release formulation was discontinued due to business reasons unrelated to drug safety and efficacy. … In the US, viloxazine was assigned an orphan drug designation in 1984 under the brand name CATATROL: while this product was intended to treat cataplexy and narcolepsy, the drug was never approved for these
Categories: Adrenergic alpha-1 Receptor AntagonistsEtuvetidigene Autotemcel
go.drugbank.com/drugs/DB17593ApprovedInvestigational[L54693] WAS is a rare X-linked disorder caused by a mutation in the gene encoding the WAS protein, leading to a compromised immune system. … [A274878] The WAS protein is expressed on non-erythroid hematopoietic cells and regulates the function of actin filaments in the cytoskeleton.[A274878]
Synonyms: Autologous CD34+ cells transfected with lentiviral vector containing the human WAS cDNA (Telethon 003)Vadadustat
go.drugbank.com/drugs/DB12255ApprovedInvestigationalOne of the most common symptoms of advanced renal disease is anemia, caused primarily by the inability of the kidney to respond to anemic conditions with a corresponding increase in [erythropoietin] (EPO … alfa], to counter the decrease in endogenous EPO production.
Respiratory syncytial virus vaccine, adjuvanted
go.drugbank.com/drugs/DB17762ApprovedInvestigationalthe accompanying vial of AS01E adjuvant as the adjuvant suspension component. … [L46347] On May 3, 2023, it was approved by the FDA for immunization against lower respiratory tract disease (LRTD) as the first respiratory syncytial virus (RSV) vaccine approved in the United States
Nitisinone
go.drugbank.com/drugs/DB00348ApprovedIt is used in the treatment of hereditary tyrosinemia type 1 and Alkaptonuria. It is sold under the brand names Orfadin and Harliku. [L53253, L53258]
Mosunetuzumab
go.drugbank.com/drugs/DB15434ApprovedInvestigational[L42230] It can recognize and bind two different targets simultaneously, CD20 on cancer B-cells and CD3 on T-cells, allowing it to redirect T-cell cytotoxic activity to cancer cells. … [A249320,A249390] Mosunetuzumab has the potential to circumvent resistance to [rituximab] in patients with follicular lymphoma,[A249320,L42230] and unlike CAR-T therapies such as [axicabtagene ciloleucel